natgillin/translations-raw huggingface dataset:
Patients (n = 578) were randomised 1:1 to receive either IMBRUVICA 420 mg daily or placebo in combination with BR until disease progression, or unacceptable toxicity.
Bolnike (n = 578) so randomizirali 1:1 na prejemanje 420 mg zdravila IMBRUVICA na dan ali placeba v kombinaciji z BR do napredovanja bolezni ali do nesprejemljivega toksičnega delovanja zdravila.
patients (n = 61)
Bolniki ITT* (n = 61)
Patients (N = 723) with advanced RCC whose disease had progressed on or after treatment with one prior systemic therapy, including sunitinib-, bevacizumab-, temsirolimus-, or cytokine-containing regimens were randomised (1:1) to receive axitinib (N = 361) or sorafenib (N = 362).
Bolniki (n = 723) z napredovalim RCC, pri katerih je bolezen napredovala med zdravljenjem ali po zdravljenju z eno predhodno sistemsko terapijo (ki je vključevala režime, v katerih so bili uporabljeni sunitinib, bevacizumab, temsirolimus ali citokin), so bili randomizirani (1:1) v skupino, ki je prejemala aksitinib (n = 361) oziroma sorafenib (n = 362).
Patients (n=1,822) previously enrolled in Phase 2 or 3 vedolizumab studies were eligible to enrol in an ongoing open-label study and received vedolizumab 300 mg every four weeks.
Bolniki (n=1.822), ki so že bili vključeni v študije vedolizumaba 2. ali 3. faze, so bili primerni za vključitev v odprto študijo, ki še poteka, in prejemajo vedolizumab v odmerku 300 mg na vsake štiri tedne.
Patients (n=368) were randomised in a double-blind fashion (3:2) to receive two doses of vedolizumab 300 mg or placebo at Week 0 and Week 2.
Bolnike (n=368) so randomizirali na dvojno slep način (3:2) na dva odmerka vedolizumaba 300 mg ali placeba na 0. teden in 2. teden.
Patients (N=658) with advanced RCC with a clear cell component who had previously received at least 1 prior VEGF receptor tyrosine kinase inhibitor (VEGFR TKI) were randomized (1:1) to receive CABOMETYX (N=330) or everolimus (N=328).
Bolniki (N = 658) z napredovalim KLC s kompomento svetle celice, ki so pred tem prejeli vsaj 1 predhodni zaviralec receptorskih tirozin-kinaz VEGF (VEGFR TKI), so bili randomizirani (1 : 1) za prejemanje zdravila CABOMETYX (N = 330) ali everolimusa (N = 328).
Patients (which includes younger children with sJIA or pJIA who may be less able to communicate their symptoms) and parents/guardians of sJIA or pJIA patients, should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment.
Bolnikom (tudi mlajšim otrokom s sJIA ali pJIA, ki še ne znajo dobro sporočati svojih simptomov) in staršem/skrbnikom bolnikov s sJIA in pJIA morate naročiti, naj se nemudoma posvetujejo z zdravnikom, če se pojavi kakršenkoli simptom okužbe, da bodo deležni hitre ocene stanja in ustreznega zdravljenja.
Patients (≥ 18 years) were randomised in a 2:1 ratio to receive a starting dose of romiplostim 1 µg/kg or placebo.
Bolnike (stare ≥ 18 let) so v razmerju 2:1 randomizirali na skupino, ki je prejemala začetni odmerek 1 µg/kg romiplostima in skupino, ki je prejemala placebo.
Patients 40 kg and above
bolniki s telesno maso 40 kg in več
Patients 40 kg and above*
bolniki s telesno maso 40 kg in več
Patients 40 kg and above**
bolniki s telesno maso 40 kg in več
Patients < 60 kg
Bolniki < 60 kg
Patients <18 years of age:
Bolniki, stari manj kot 18 let:
Patients <30 kg also receiving valproate medication:
Bolniki s telesno maso, manjšo od 30 kg, ki jemljejo tudi valproat:
Patients <30 kg also receiving valproate:
Bolniki s telesno maso, manjšo od 30 kg, ki jemljejo tudi valproat:
Patients <30 kg also receiving valproate:
Bolniki s telesno maso, manjšo od 30 kg, ki prejemajo tudi valproat:
Patients <30 kg not receiving valproate:
Bolniki s telesno maso, manjšo od 30 kg, ki ne jemljejo valproata:
Patients <30 kg not receiving valproate:
Bolniki s telesno maso, manjšo od 30 kg, ki ne prejemajo valproata:
Patients >100 kg: 30 ml of BRINAVESS 20 mg/ml is added to 120 ml of diluent.
Bolniki s telesno maso > 100 kg: 30 ml zdravila BRINAVESS 20 mg/ml dodajte 120 ml vehikla.
Patients >75 years received a dexamethasone dose of 20 mg once daily on Days 1, 8, 15, and 22 of each 28-day cycle.
Bolniki, starejši od 75 let, so prejemali odmerek deksametazona 20 mg enkrat na dan 1., 8., 15. in 22. dne vsakega 28-dnevnega cikla.
Patients achieving at least a ACR Pedi 30 response at the end of Period A were randomized into a double-blind, withdrawal phase (Period B), and received either abatacept or placebo for 6 months or until JIA disease flare as defined in the study.
Bolniki, ki so na koncu obdobja A dosegli odziv vsaj ACR Pedi 30, so bili randomizirani v dvojno slepo odtegnitveno fazo (obdobje B) in prejemali abatacept ali placebo 6 mesecev ali dokler se ni stanje juvenilnega idiopatskega artritisa poslabšalo kot je bilo določeno v študiji.
Patients achieving at least partial response (PR) were entered on the MabThera subcutaneous formulation maintenance therapy once every 8 weeks for 24 months.
Bolniki, ki so dosegli vsaj delni odgovor (PR), so vstopili v vzdrževalno zdravljenje s podkožno obliko zdravila MabThera enkrat na 8 tednov za 24 mesecev.
Patients achieving at least PR were entered on MabThera intravenous formulation maintenance therapy once every 8 weeks for 24 months.
Bolniki, ki so dosegli vsaj delni odgovor (PR), so vstopili v vzdrževalno zdravljenje z intravensko obliko zdravila MabThera enkrat na 8 tednov za 24 mesecev.
Patients achieving early molecular response had a lower risk of transformation, higher rate of progression-free survival (PFS) and higher rate of overall survival (OS), as shown in Table 6.
Bolniki, ki so dosegli zgodnji molekularni odziv, so imeli manjše tveganje za transformacijo, višji delež preživetja brez napredovanja bolezni in višji delež celokupnega preživetja, kot je prikazano v preglednici 6.
Patients achieving target platelet counts & initiating antiviral therapy c
Bolniki, ki so dosegli ciljno število trombocitov & začeli s protivirusnim zdravljenjem c
Patients achieving ≥ 2 x 106 cells/kg in ≤ 4 apheresis days and successful engraftment
bolniki z ≥ 2 x 106 celicami/kg v ≤ 4 dneh afereze in uspešnim vcepljanjem
Patients achieving ≥ 5 x 106 cells/kg in ≤ 4 apheresis days and successful engraftment
bolniki z ≥ 5 x 106 celicami/kg v ≤ 4 dneh afereze in uspešnim vcepljanjem
Patients achieving ≥ 6 x 106 cells/kg in ≤ 2 apheresis days and successful engraftment
bolniki z ≥ 6 x 106 celicami/kg v ≤ 2 dneh afereze in uspešnim vcepljanjem
Patients added Vimpat at a dose of 200 mg, 400 mg or 600 mg a day, or placebo to their existing treatment of up to three other anti-epileptic medicines.
Bolniki so poleg primarnega zdravljenja z največ tremi zdravili proti epilepsiji začeli uporabljati tudi zdravilo Vimpat v odmerku 200 mg, 400 mg ali 600 mg na dan ali placebo.
Patients adding Humira also had less joint damage and experienced less reduction in physical function after a year.
Bolniki, ki so kot dodatek prejemali zdravilo Humira, so imeli po enem letu zdravljenja tudi manj poškodb sklepov in manjše poslabšanje telesnih zmogljivosti.
Patients adding Inovelon also had a 42.5% reduction in the number of ‘tonic-atonic’ seizures (a common type of fit in patients with Lennox-Gastaut syndrome that often involves the patient dropping to the floor), compared with a 1.9% increase in those adding placebo.
Pri bolnikih, ki so dodajali zdravilo Inovelon, so opazili tudi zmanjšanje števila tonično-atoničnih napadov (vrsta napada, ki je običajno prisotna pri bolnikih z Lennox-Gastautovim sindromom, pri katerem bolnik pogosto pade na tla) za 42,5 %, v primerjavi z zvečanjem za 1,9 % pri tistih, ki so kot dodatek jemali placebo.
Patients administered the higher dose of 175 mg of Torisel for the initial treatment of MCL may receive up to 4.85 g of ethanol (equivalent to 123 ml beer or 51 ml wine per dose).
Bolniki, ki za začetek zdravljenja MCL prejmejo večji odmerek zdravila Torisel, to je 175 mg, utegnejo prejeti do 4,85 g etanola (kar ustreza 123 ml piva oziroma 51 ml vina na odmerek).
Patients administering Velosulin by CSII must have injection syringes and alternative insulin readily available in case of emergency or pump interruption or failure, in order that insulin can be administered by subcutaneous injection.
Bolniki, ki Velosulin uporabljajo v stalni subkutani infuziji, morajo imeti pri roki brizge in drug insulin, ce se zgodi, da crpalka preneha delovati ali odpove; tako si lahko insulin aplicirajo s subkutano injekcijo.
Patients aged 3 to 13 years: for children, the recommended starting dose is 50-55 mg/kg BID or if using a TID regimen, 25 – 35 mg/kg body weight per dose.
Bolniki, stari 3 do 13 let: za otroke je priporočeni začetni odmerek 50 do 55 mg/kg telesne mase dvakrat na dan ali 25 do 35 mg/kg telesne mase trikrat na dan.
Patients aged 3 to 13 years: for children, the recommended starting dose is 50-55 mg/kg BID or, if using a TID regimen, 25 – 35 mg/kg body weight per dose.
Bolniki, stari 3 do 13 let: za otroke je priporočeni začetni odmerek 50 do 55 mg/kg telesne mase dvakrat na dan ali 25 do 35 mg/kg telesne mase trikrat na dan.
Patients aged 65 years and over
Bolniki, stari 65 let in več
Patients aged 80 years or above should be treated with a daily dose of 220 mg taken as one 110 mg capsule twice daily due to the increased risk of bleeding in this population.
Bolnike, stare 80 let in več, je treba zaradi povečanega tveganja krvavitve v tej populaciji zdraviti z dnevnimi odmerki po 220 mg, to je z eno kapsulo po 110 mg dvakrat na dan.
Patients aged >2 months to 2 years of age
Bolniki stari > 2 meseca do 2 let
Patients aged over 65 years should start with a 1 mg dose once a day, and this can be increased to 2 mg once a day if needed.
Bolniki, starejši od 65 let, naj začnejo z 1-miligramskim odmerkom enkrat na dan, po potrebi pa se lahko odmerek zviša na 2 mg enkrat na dan.
Patients allergic to paraaminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine and/or prilocaine; however, Fortacin should be used with caution in patients with a history (or partner with a history) of sensitivities to medicinal products, especially if the aetiologic agent is uncertain.
Pri bolnikih, ki so alergični na derivate paraaminobenzojske kisline (prokain, tetrakain, benzokain itd.), niso zabeležili navzkrižne občutljivosti na lidokain in/ali prilokain; vendar je potrebna previdnost pri uporabi zdravila Fortacin pri bolnikih (ali njihovih partnerkah) s preobčutljivostmi na zdravila v anamnezi, zlasti kadar etiološki dejavnik ni znan.
patients already on tacrolimus, it is
Kadar se pri bolnikih, ki že dobivajo takrolimus, vpelje
Patients also had plaque psoriasis with a qualifying target lesion  2 cm in diameter.
Bolniki so imeli tudi psoriazo v plakih, pri čemer so za mejno velikost lezij šteli tiste z ≥ 2 cm premera.
Patients also required lower administration of erythropoietin/darbopoietin (10.4 % versus 18.1 %, p < 0.001), G-CSF/GM-CSF (3.1 % versus 6.1 %, p = 0.004), and iron preparations (4.3 % versus 7.0 %, p = 0.021).
Bolniki so potrebovali tudi nižje odmerjanje eritropoetin/darbepoetina (10,4 % proti 18,1 %, p < 0,001), G-CSF/GM-CSF (3,1 % proti 6,1 %, p = 0,004) in pripravkov z železom (4,3 % proti 7,0 %, p = 0,021).
Patients and caregivers must be instructed to properly dispose of all unused, partially used and used PecFent bottles.
Bolniki in negovalci morajo biti poučeni o tem, kako se pravilno odvržejo vse neporabljene, delno porabljene in porabljene steklenice zdravila PecFent.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathologic gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine.
Bolniki in negovalci se morajo zavedati, da se lahko pri bolnikih, zdravljenih z agonisti dopamina, vključno z rotigotinom, pojavijo vedenjski simptomi motenj kontrole dražljajev kot sopatološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno zapravljanje ali nakupovanje, prenajedanje in kompulzivno prehranjevanje.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathologic gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine.
Bolniki in negovalci se morajo zavedati, da se lahko pri bolnikih, zdravljenih z agonisti dopamina, vključno z rotigotinom,pojavijo vedenjski simptomi motenj kontrole dražljajev kot so patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno zapravljanje ali nakupovanje, prenajedanje in kompulzivno prehranjevanje.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathologic gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine.
Bolniki in skrbniki se morajo zavedati, da se lahko pri bolnikih, zdravljenih z agonisti dopamina, vključno z rotigotinom, pojavijo vedenjski simptomi motenj kontrole dražljajev kot so patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno zapravljanje ali nakupovanje, prenajedanje in kompulzivno prehranjevanje.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Levodopa/Carbidopa/Entacapone Orion.
Bolnike in njihove skrbnike je treba opozoriti, da pri bolnikih, ki se zdravijo z agonisti dopamina in/ali drugimi dopaminergičnimi zdravljenji, ki vsebujejo levodopo, vključno z zdravilom Levodopa/Carbidopa/Entacapone Orion, lahko pride do vedenjskih simptomov, ki so znak motenj pri obvladovanju impulzov, kar vključuje patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno zapravljanje ali nakupovanje, prenajedanje in kompulzivno prenajedanje.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Oprymea.
Bolnikom in negovalcem je treba povedati, da se lahko pri bolnikih, ki se zdravijo z dopaminskimi agonisti, tudi z zdravilom Oprymea, pojavijo vedenjski simptomi motenj nadzora impulzov, kot so patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno trošenje denarja ali nakupovanje, prenajedanje in kompulzivno uživanje hrane.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including pramipexole.
Bolnikom in negovalcem je treba povedati, da se lahko pri bolnikih, ki se zdravijo z dopaminskimi agonisti, tudi s pramipeksolom, pojavijo vedenjski simptomi motenj nadzora impulzov, kot so patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno trošenje denarja ali nakupovanje, prenajedanje in kompulzivno uživanje hrane.
Patients and physicians are advised to be observant for signs and symptoms of bleeding including petechiae, epistaxis and gastrointestinal haemorrhage, especially in case of concomitant medication susceptible to induce bleeding (see section 4.8).
Bolnikom in zdravnikom se svetuje, naj bodo pozorni na znake in simptome krvavitev, vključno s petehijami, epistakso in gastrointestinalno krvavitvijo, posebno v primeru sočasnega jemanja zdravil, ki lahko povzročijo krvavitve (glejte poglavje 4.8).
Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products susceptible to induce bleeding (see section 4.8 Haemorrhagic disorders).
Za bolnike in zdravnike velja nasvet, naj bodo pozorni na znake in simptome krvavitev, vključno s petehijami in epistakso, posebno še pri bolnikih, ki sočasno prejemajo zdravila, ki lahko povzročijo krvavitev (glejte poglavje 4.8, Hemoragične bolezni).
Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products susceptible to induce bleeding (see section 4.8, Haemorrhagic disorders).
Bolnikom in zdravnikom se svetuje, naj bodo pozorni na znake in simptome krvavitev, vključno s petehijami in epistaksami, posebno pri bolnikih, ki sočasno prejemajo zdravila, ki lahko povzročijo krvavitev (glejte poglavje 4.8 Hemoragične bolezni).
Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products that increase susceptibility to bleeding (see section 4.8 Haemorrhagic disorders).
Za bolnike in zdravnike velja nasvet, naj bodo pozorni na znake in simptome krvavitev, vključno s petehijami in epistakso, posebno še pri bolnikih, ki sočasno prejemajo zdravila, ki zvečujejo dovzetnost za krvavitve (glejte poglavje 4.8, Hemoragične bolezni).
Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in patients receiving concomitant medicinal products that increase susceptibility to bleeding (see section 4.8, Haemorrhagic disorders).
Za bolnike in zdravnike velja nasvet, naj bodo pozorni na znake in simptome krvavitev, vključno s petehijami in epistakso, posebno še pri bolnikih, ki sočasno prejemajo zdravila, ki zvečujejo dovzetnost za krvavitve (glejte poglavje 4.8, Hemoragične bolezni).
Patients and prescribers must be aware that due to potential pharmacokinetic interactions, STAYVEER may render hormonal contraceptives ineffective (see section 4.5).
Bolnica in zdravnik, ki zdravilo predpiše, se morata zavedati, da lahko zaradi možnih farmakokinetičnih interakcij zdravilo STAYVEER povzroči neučinkovitost hormonske kontracepcije (glejte poglavje 4.5).
Patients and prescribers must be aware that due to potential pharmacokinetic interactions, Tracleer may render hormonal contraceptives ineffective (see section 4.5).
Bolnica in zdravnik, ki zdravilo predpiše, se morata zavedati, da lahko zaradi možnih farmakokinetičnih interakcij zdravilo Tracleer povzroči neučinkovitost hormonske kontracepcije (glejte poglavje 4.5).
Patients and their carers must be instructed that Effentora contains an active substance in an amount that can be fatal, especially to a child.
Bolnike in njihove skrbnike je treba opozoriti, da vsebuje zdravilo Effentora zdravilno učinkovino v količini, ki je lahko smrtna, posebej za otroke.
Patients and/or parents or the legal responsible person must be able to follow directions regarding the administration of this medicinal product, their monitoring and care.
Bolniki in/ali starši ali zakoniti zastopniki morajo biti zmožni slediti navodilom, ki zadevajo dajanje tega zdravila, spremljanje zdravljenja in nego.
Patients appear to be at highest risk for these reactions early in the course of therapy; the onset of the reaction occurring in the majority of cases within the first month of treatment.
Kaže, da je tveganje za te reakcije največje kmalu po začetku zdravljenja; v večini primerov so reakcije nastopile v prvem mesecu zdrvaljenja.
Patients are advised not to drive or operate machinery while taking anagrelide if dizziness is experienced.
V primeru omotice ob jemanju anagrelida naj bolniki ne vozijo ali upravljajo s stroji.
Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.
Bolnikom svetujemo, naj ne vozijo ali upravljajo s stroji, dokler ni potrjeno, da zdravilo ne vpliva na njihovo sposobnost izvajanja dejavnosti.
Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.
Bolniki naj ne vozijo, ne upravljajo zapletenih strojev in ne opravljajo drugih potencialno nevarnih dejavnosti, dokler ni znano, ali to zdravilo vpliva na njihovo sposobnost za te dejavnosti.
Patients are advised to avoid or reduce exposure to direct sunlight (including sunlamps).
Bolnikom je treba svetovati, da se izogibajo izpostavljenosti neposredni sončni svetlobi ali jo zmanjšajo (vključno z ultravijoličnimi svetilkami).
Patients are advised to discontinue therapy with naloxegol and promptly notify their physician if they develop unusually severe or persistent abdominal pain.
Bolnikom je treba naročiti, naj v primeru nenavadno hudih ali dolgotrajnih bolečin v trebuhu nehajo jemati naloksegol in nemudoma obvestijo zdravnika.
Patients are eligible for Herceptin treatment if they show strong HER2 overexpression as described by a 3+ score by IHC or a positive FISH or CISH result.
Za zdravljenje z zdravilom Herceptin so primerni bolniki, katerih rezultat čezmernega izražanja HER2 po metodi IHC znaša 3+ ali bolniki, katerih rezultat metod FISH ali CISH je pozitiven.
Patients are eligible for Herceptin treatment if they show strong HER2 overexpression as described by a 3+ score by IHC or a positive FISH or CISH result.
Za zdravljenje z zdravilom Herceptin so primerni bolniki, katerih rezultat čezmernega izražanja HER2 po metodi IHC znaša 3+, ali bolniki, katerih rezultat metod FISH ali CISH je pozitiven.
Patients are eligible for Lynparza treatment if they have a confirmed deleterious or suspected deleterious BRCA mutation (i.e. a mutation that disrupts normal gene function) in either the germline or the tumour (detected using an appropriately validated test).
Za zdravljenje z zdravilom Lynparza so primerne tiste bolnice, ki imajo potrjeno ali domnevno škodljivo mutacijo gena BRCA (tj. mutacijo, ki onemogoča normalno delovanje gena) bodisi germinalno ali v tumorju (potrjeno z uporabo ustrezno validirane preiskave).
Patients are to be advised that they may develop fatigue, somnolence, or confusion during treatment with IntronA, and therefore it is recommended that they avoid driving or operating machinery.
Bolnike poučite, da bodo med zdravljenjem z zdravilom IntronA lahko utrujeni, zaspani ali zmedeni in da je zato priporočljivo, da se izogibajo vožnji ali delu s stroji.
Patients are usually well-controlled by maintaining the recommended starting dose (1-2 mg/kg/day).
Pri bolnikih je z vzdrževanjem priporočenega začetnega odmerka (1–2 mg/kg/dan) bolezen navadno dobro urejena.
Patients assessed by the investigator to be in clinical response at week 10 were randomised and received
Bolnike, za katere je raziskovalec v 10. tednu ocenil, da kažejo klinični odziv na zdravljenje, so naključno razvrstili v dve skupini.
Patients assessed by the investigator to be in clinical response at week 10 were randomised and received 5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.
Bolnike, za katere je raziskovalec v 10. tednu ocenil, da kažejo klinični odziv na zdravljenje, so naključno razvrstili v dve skupini.
Patients at high immunological risk of graft loss were not studied in sufficient number in the ciclosporin elimination-Rapamune maintenance studies and are not recommended for this treatment regimen.
Bolnikov z visokim imunskim tveganjem za zavrnitev presadka je bilo v študijah s takšno shemo zdravljenja (ukinitev ciklosporina in vzdrževalno zdravljenje z zdravilom Rapamune) premalo, da bi jo lahko priporočali tudi pri njih.
Patients at high surgical mortality risk and with intrinsic risk factors for thromboembolic events
Bolniki, pri katerih obstaja med operacijo veliko tveganje smrti in ki imajo intrinzične dejavnike tveganja za trombembolične dogodke